---
document_datetime: 2025-12-02 06:15:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tigecycline-accord.html
document_name: tigecycline-accord.html
version: success
processing_time: 0.1383281
conversion_datetime: 2025-12-25 10:09:25.517984
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tigecycline Accord

[RSS](/en/individual-human-medicine.xml/67299)

##### Authorised

This medicine is authorised for use in the European Union

tigecycline Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tigecycline Accord](#news-on)
- [Related content](#related-content-1589)
- [Product information - with tracked changes](#product-information-with-tracked-changes-79662)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Tigecycline Accord is a medicine used to treat adults and children older than eight years with complicated infections of the skin and soft tissue (the tissue below the skin), but not foot infections in people with diabetes. It is also used to treat complicated infections in the abdomen. 'Complicated' means that the infection is difficult to treat because it has spread, or the patient has other conditions that makes treatment difficult. Tigecycline Accord should be used only when other antibiotics are not suitable. Before using Tigecycline Accord, doctors should consider official guidance on the appropriate use of antibiotics.

Tigecycline Accord is a 'generic medicine'. This means that Tigecycline Accord contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Tygacil. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf) .

Tigecycline Accord contains the active substance tigecycline.

Expand section

Collapse section

## How is Tigecycline Accord used?

Tigecycline Accord is available as a powder that is made up into a solution for infusion (drip) into a vein. In adults, the recommended dose of Tigecycline Accord is a starting dose of 100 mg, followed by 50 mg every 12 hours for five to 14 days. Each infusion should last between 30 and 60 minutes. The length of treatment depends on where the infection is, how severe it is, and the patient's response to treatment. Doses are lower in patients with severe liver problems.

In children above eight years of age, treatment is only given after consulting with a doctor with appropriate experience in the management of infectious diseases, and should be given as an infusion over a period of 60 minutes. In children from 8 to 12 years old a dose of 1.2 mg per kilogram body weight is given by infusion into a vein every 12 hours, up to a maximum dose of 50 mg every 12 hours. Treatment lasts from 5 to 14 days. In children from 12 to 18 years a dose of 50 mg is given every 12 hours for a period of 5 to 14 days.

The medicine can only be obtained with a prescription.

For more information about using Tigecycline Accord, see the package leaflet or contact your doctor or pharmacist.

## How does Tigecycline Accord work?

The active substance in Tigecycline Accord, tigecycline, belongs to a group of antibiotics called 'glycylcyclines'. It works by blocking the bacteria's ribosomes, the parts of the cell where new proteins are made. By blocking the production of new proteins, the bacteria cannot multiply and they eventually die.

## How has Tigecycline Accord been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Tygacil, and do not need to be repeated for Tigecycline Accord.

As for every medicine, the company provided studies on the quality of Tigecycline Accord. There was no need for 'bioequivalence' studies to investigate whether Tigecycline Accord is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Tigecycline Accord is given by infusion into a vein, so the active substance is delivered straight into the bloodstream.

## What are the benefits and risks of Tigecycline Accord?

Because Tigecycline Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Tigecycline Accord authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Tigecycline Accord has been shown to be comparable to Tygacil. Therefore, the Agency's view was that, as for Tygacil, the benefits of Tigecycline Accord outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Tigecycline Accord?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tigecycline Accord have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tigecycline Accord are continuously monitored. Side effects reported with Tigecycline Accord are carefully evaluated and any necessary action taken to protect patients.

## Other information about Tigecycline Accord

Tigecycline Accord received a marketing authorisation valid throughout the EU on 17 April 2020.

Tigecycline Accord : EPAR - Medicine overview

Reference Number: EMA/134692/2020

English (EN) (145.5 KB - PDF)

**First published:** 24/04/2020

[View](/en/documents/overview/tigecycline-accord-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-685)

български (BG) (170.06 KB - PDF)

**First published:**

24/04/2020

[View](/bg/documents/overview/tigecycline-accord-epar-medicine-overview_bg.pdf)

español (ES) (146.65 KB - PDF)

**First published:**

24/04/2020

[View](/es/documents/overview/tigecycline-accord-epar-medicine-overview_es.pdf)

čeština (CS) (167.58 KB - PDF)

**First published:**

24/04/2020

[View](/cs/documents/overview/tigecycline-accord-epar-medicine-overview_cs.pdf)

dansk (DA) (146.16 KB - PDF)

**First published:**

24/04/2020

[View](/da/documents/overview/tigecycline-accord-epar-medicine-overview_da.pdf)

Deutsch (DE) (149.88 KB - PDF)

**First published:**

24/04/2020

[View](/de/documents/overview/tigecycline-accord-epar-medicine-overview_de.pdf)

eesti keel (ET) (135.15 KB - PDF)

**First published:**

24/04/2020

[View](/et/documents/overview/tigecycline-accord-epar-medicine-overview_et.pdf)

ελληνικά (EL) (169.39 KB - PDF)

**First published:**

24/04/2020

[View](/el/documents/overview/tigecycline-accord-epar-medicine-overview_el.pdf)

français (FR) (148.51 KB - PDF)

**First published:**

24/04/2020

[View](/fr/documents/overview/tigecycline-accord-epar-medicine-overview_fr.pdf)

hrvatski (HR) (167.65 KB - PDF)

**First published:**

24/04/2020

[View](/hr/documents/overview/tigecycline-accord-epar-medicine-overview_hr.pdf)

italiano (IT) (145.15 KB - PDF)

**First published:**

24/04/2020

[View](/it/documents/overview/tigecycline-accord-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (185.02 KB - PDF)

**First published:**

24/04/2020

[View](/lv/documents/overview/tigecycline-accord-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (168.64 KB - PDF)

**First published:**

24/04/2020

[View](/lt/documents/overview/tigecycline-accord-epar-medicine-overview_lt.pdf)

magyar (HU) (169.2 KB - PDF)

**First published:**

24/04/2020

[View](/hu/documents/overview/tigecycline-accord-epar-medicine-overview_hu.pdf)

Malti (MT) (170.06 KB - PDF)

**First published:**

24/04/2020

[View](/mt/documents/overview/tigecycline-accord-epar-medicine-overview_mt.pdf)

Nederlands (NL) (147.11 KB - PDF)

**First published:**

24/04/2020

[View](/nl/documents/overview/tigecycline-accord-epar-medicine-overview_nl.pdf)

polski (PL) (171.2 KB - PDF)

**First published:**

24/04/2020

[View](/pl/documents/overview/tigecycline-accord-epar-medicine-overview_pl.pdf)

português (PT) (146.85 KB - PDF)

**First published:**

24/04/2020

[View](/pt/documents/overview/tigecycline-accord-epar-medicine-overview_pt.pdf)

română (RO) (166.66 KB - PDF)

**First published:**

24/04/2020

[View](/ro/documents/overview/tigecycline-accord-epar-medicine-overview_ro.pdf)

slovenčina (SK) (168.83 KB - PDF)

**First published:**

24/04/2020

[View](/sk/documents/overview/tigecycline-accord-epar-medicine-overview_sk.pdf)

slovenščina (SL) (165.08 KB - PDF)

**First published:**

24/04/2020

[View](/sl/documents/overview/tigecycline-accord-epar-medicine-overview_sl.pdf)

Suomi (FI) (144.45 KB - PDF)

**First published:**

24/04/2020

[View](/fi/documents/overview/tigecycline-accord-epar-medicine-overview_fi.pdf)

svenska (SV) (133.73 KB - PDF)

**First published:**

24/04/2020

[View](/sv/documents/overview/tigecycline-accord-epar-medicine-overview_sv.pdf)

Tigecycline Accord : EPAR - Risk-management-plan summary

English (EN) (80.03 KB - PDF)

**First published:** 24/04/2020

[View](/en/documents/rmp-summary/tigecycline-accord-epar-risk-management-plan-summary_en.pdf)

## Product information

Tigecycline Accord : EPAR - Product Information

English (EN) (368.29 KB - PDF)

**First published:** 24/04/2020

**Last updated:** 26/09/2025

[View](/en/documents/product-information/tigecycline-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-626)

български (BG) (531 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/bg/documents/product-information/tigecycline-accord-epar-product-information_bg.pdf)

español (ES) (454.9 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/es/documents/product-information/tigecycline-accord-epar-product-information_es.pdf)

čeština (CS) (484.41 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/cs/documents/product-information/tigecycline-accord-epar-product-information_cs.pdf)

dansk (DA) (467.86 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/da/documents/product-information/tigecycline-accord-epar-product-information_da.pdf)

Deutsch (DE) (445.47 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/de/documents/product-information/tigecycline-accord-epar-product-information_de.pdf)

eesti keel (ET) (439.21 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/et/documents/product-information/tigecycline-accord-epar-product-information_et.pdf)

ελληνικά (EL) (928.37 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/el/documents/product-information/tigecycline-accord-epar-product-information_el.pdf)

français (FR) (497.01 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/fr/documents/product-information/tigecycline-accord-epar-product-information_fr.pdf)

hrvatski (HR) (509.36 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/hr/documents/product-information/tigecycline-accord-epar-product-information_hr.pdf)

íslenska (IS) (453.91 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/is/documents/product-information/tigecycline-accord-epar-product-information_is.pdf)

italiano (IT) (539.71 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/it/documents/product-information/tigecycline-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (485.72 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/lv/documents/product-information/tigecycline-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (444.01 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/lt/documents/product-information/tigecycline-accord-epar-product-information_lt.pdf)

magyar (HU) (496.46 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/hu/documents/product-information/tigecycline-accord-epar-product-information_hu.pdf)

Malti (MT) (535.34 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/mt/documents/product-information/tigecycline-accord-epar-product-information_mt.pdf)

Nederlands (NL) (484.76 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/nl/documents/product-information/tigecycline-accord-epar-product-information_nl.pdf)

norsk (NO) (438.05 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/no/documents/product-information/tigecycline-accord-epar-product-information_no.pdf)

polski (PL) (518.71 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/pl/documents/product-information/tigecycline-accord-epar-product-information_pl.pdf)

português (PT) (442.24 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/pt/documents/product-information/tigecycline-accord-epar-product-information_pt.pdf)

română (RO) (499.2 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/ro/documents/product-information/tigecycline-accord-epar-product-information_ro.pdf)

slovenčina (SK) (522.13 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/sk/documents/product-information/tigecycline-accord-epar-product-information_sk.pdf)

slovenščina (SL) (446.17 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/sl/documents/product-information/tigecycline-accord-epar-product-information_sl.pdf)

Suomi (FI) (440.21 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/fi/documents/product-information/tigecycline-accord-epar-product-information_fi.pdf)

svenska (SV) (435.18 KB - PDF)

**First published:**

24/04/2020

**Last updated:**

26/09/2025

[View](/sv/documents/product-information/tigecycline-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000300796 25/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tigecycline Accord : EPAR - All Authorised presentations

English (EN) (27.43 KB - PDF)

**First published:** 24/04/2020

[View](/en/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-39)

български (BG) (51.1 KB - PDF)

**First published:**

24/04/2020

[View](/bg/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (35.32 KB - PDF)

**First published:**

24/04/2020

[View](/es/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (34.09 KB - PDF)

**First published:**

24/04/2020

[View](/cs/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (27.02 KB - PDF)

**First published:**

24/04/2020

[View](/da/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (27.69 KB - PDF)

**First published:**

24/04/2020

[View](/de/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (27.42 KB - PDF)

**First published:**

24/04/2020

[View](/et/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (49.25 KB - PDF)

**First published:**

24/04/2020

[View](/el/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (27.69 KB - PDF)

**First published:**

24/04/2020

[View](/fr/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (55.65 KB - PDF)

**First published:**

24/04/2020

[View](/hr/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (27.27 KB - PDF)

**First published:**

24/04/2020

[View](/is/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (27.53 KB - PDF)

**First published:**

24/04/2020

[View](/it/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (46.87 KB - PDF)

**First published:**

24/04/2020

[View](/lv/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (47.19 KB - PDF)

**First published:**

24/04/2020

[View](/lt/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (35.01 KB - PDF)

**First published:**

24/04/2020

[View](/hu/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (47.23 KB - PDF)

**First published:**

24/04/2020

[View](/mt/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (27.61 KB - PDF)

**First published:**

24/04/2020

[View](/nl/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (27.76 KB - PDF)

**First published:**

24/04/2020

[View](/no/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (37.03 KB - PDF)

**First published:**

24/04/2020

[View](/pl/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.47 KB - PDF)

**First published:**

24/04/2020

[View](/pt/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (46.47 KB - PDF)

**First published:**

24/04/2020

[View](/ro/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (35.26 KB - PDF)

**First published:**

24/04/2020

[View](/sk/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (35.44 KB - PDF)

**First published:**

24/04/2020

[View](/sl/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (16.41 KB - PDF)

**First published:**

24/04/2020

[View](/fi/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (27.91 KB - PDF)

**First published:**

24/04/2020

[View](/sv/documents/all-authorised-presentations/tigecycline-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tigecycline Accord Active substance tigecycline International non-proprietary name (INN) or common name tigecycline Therapeutic area (MeSH)

- Soft Tissue Infections
- Intraabdominal Infections
- Bacterial Infections
- Skin Diseases, Infectious

Anatomical therapeutic chemical (ATC) code J01AA12

### Pharmacotherapeutic group

Antibacterials for systemic use

### Therapeutic indication

Tygecycline Accord is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1):

- Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections (see section 4.4)
- Complicated intra-abdominal infections (cIAI)

Tygecycline Accord should be used only in situations where other alternative antibiotics are not suitable (see sections 4.4, 4.8 and 5.1).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

## Authorisation details

EMA product number EMEA/H/C/005114

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Marketing authorisation issued 17/04/2020 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tigecycline Accord : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (458.34 KB - PDF)

**First published:** 05/06/2025

**Last updated:** 26/09/2025

[View](/en/documents/procedural-steps-after/tigecycline-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tigecycline Accord : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (126.84 KB - PDF)

**First published:** 29/11/2021

**Last updated:** 05/06/2025

[View](/en/documents/procedural-steps-after/tigecycline-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Tigecycline Accord : EPAR - Public assessment report

Adopted

Reference Number: EMA/140293/2020

English (EN) (409.77 KB - PDF)

**First published:** 24/04/2020

[View](/en/documents/assessment-report/tigecycline-accord-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tigecycline Accord

Adopted

Reference Number: EMA/CHMP/73022/2020

English (EN) (148.15 KB - PDF)

**First published:** 28/02/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tigecycline-accord_en.pdf)

#### News on Tigecycline Accord

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-february-2020) 28/02/2020

#### Related content

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Tigecycline Accord : EPAR - Product information - tracked changes

English (EN) (124 KB - DOCX)

**First published:** 26/09/2025

[View](/en/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-345)

български (BG) (121.58 KB - DOCX)

**First published:**

26/09/2025

[View](/bg/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_bg.docx)

español (ES) (130.52 KB - DOCX)

**First published:**

26/09/2025

[View](/es/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_es.docx)

čeština (CS) (132.69 KB - DOCX)

**First published:**

26/09/2025

[View](/cs/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (104.89 KB - DOCX)

**First published:**

26/09/2025

[View](/da/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (113.71 KB - DOCX)

**First published:**

26/09/2025

[View](/de/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (125.03 KB - DOCX)

**First published:**

26/09/2025

[View](/et/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (112.22 KB - DOCX)

**First published:**

26/09/2025

[View](/el/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_el.docx)

français (FR) (116.82 KB - DOCX)

**First published:**

26/09/2025

[View](/fr/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (134.69 KB - DOCX)

**First published:**

26/09/2025

[View](/hr/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (122.66 KB - DOCX)

**First published:**

26/09/2025

[View](/is/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_is.docx)

italiano (IT) (144.22 KB - DOCX)

**First published:**

26/09/2025

[View](/it/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (116.31 KB - DOCX)

**First published:**

26/09/2025

[View](/lv/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (95.81 KB - DOCX)

**First published:**

26/09/2025

[View](/lt/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (109.31 KB - DOCX)

**First published:**

26/09/2025

[View](/hu/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (113.66 KB - DOCX)

**First published:**

26/09/2025

[View](/mt/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (114.94 KB - DOCX)

**First published:**

26/09/2025

[View](/nl/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (101.86 KB - DOCX)

**First published:**

26/09/2025

[View](/no/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_no.docx)

polski (PL) (117.27 KB - DOCX)

**First published:**

26/09/2025

[View](/pl/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_pl.docx)

português (PT) (121.22 KB - DOCX)

**First published:**

26/09/2025

[View](/pt/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_pt.docx)

română (RO) (115.48 KB - DOCX)

**First published:**

26/09/2025

[View](/ro/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (115.59 KB - DOCX)

**First published:**

26/09/2025

[View](/sk/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (109.8 KB - DOCX)

**First published:**

26/09/2025

[View](/sl/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (107.98 KB - DOCX)

**First published:**

26/09/2025

[View](/fi/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (108.6 KB - DOCX)

**First published:**

26/09/2025

[View](/sv/documents/product-information-tracked-changes/tigecycline-accord-epar-product-information-tracked-changes_sv.docx)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 26/09/2025

## Share this page

[Back to top](#main-content)